FACTORS PREDICTING LONG-TERM SURVIVAL IN DIFFUSE MIXED, HISTIOCYTIC, OR UNDIFFERENTIATED LYMPHOMA
- 1 January 1981
- journal article
- research article
- Vol. 58 (1) , 45-51
Abstract
Clinical and histopathologic material from 151 cases of diffuse mixed, diffuse histiocytic and diffuse undifferentiated non-Burkitt''s lymphomas was reviewed to determine the factors that predict long-term survival. Median survival of all patients was 34 mo. with 43% alive at 70 mo. Factors associated with a poor prognosis include: male sex, constitutional symptoms, advanced stage, bone marrow involvement, huge (> 10 cm) abdominal masses with gastrointestinal involvement, hepatic involvement. Hb < 12 g/dl or serum LDH [lactate dehydrogenase] > 250 U. The best prediction of a given patient''s survival was defined by a set of 4 variables, which includes sex, symptoms, bone marrow status and the presence or absence of a huge abdominal mass with gastrointestinal involvement. Classification of these patients according to the histopathologic categories of Rappaport or Strauchen did not define patient groups with significant differences in survival nor did these categories correlate with the previously described clinical factors. Knowledge of the distribution of these prognostic factors in any clinical trial is needed before the therapeutic results can be compared. Such data may define subsets of patients for whom current therapy is inadequate and conversely those patients for whom current therapy yields excellent long-term survival.This publication has 12 references indexed in Scilit:
- Cyclophosphamide, Vincristine, Methotrexate with Leucovorin Rescue, and Cytarabine (COMLA) Combination Sequential Chemotherapy for Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1980
- Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group studyCancer, 1979
- Clinical Relevance of the Histopathological Subclassification of Diffuse “Histiocytic” LymphomaNew England Journal of Medicine, 1978
- Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphomaArchives of internal medicine (1960), 1978
- Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapyThe American Journal of Medicine, 1977
- Survival of patients with localized histiocytic lymphomaCancer, 1977
- COMBINATION CHEMOTHERAPY OF ADVANCED NON-HODGKIN LYMPHOMA WITH BLEOMYCIN, ADRIAMYCIN, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISONE (BACOP)1977
- Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) Combination Chemotherapy in the Treatment of Advanced Diffuse Histiocytic LymphomaAnnals of Internal Medicine, 1976
- Sequential Nonsurgical and Surgical Staging of Non-Hodgkin's LymphomaAnnals of Internal Medicine, 1976
- Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and PrednisoneAnnals of Internal Medicine, 1972